An Open Label, 6-sequence, 3-period Study to Evaluate Drug-drug Interactions and Safety Between "BR3006-1", "BR3006-2", and "BR3006-3" in Healthy Volunteers
Latest Information Update: 06 Nov 2023
At a glance
- Drugs BR 3006 (Primary)
- Indications Diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
Most Recent Events
- 11 Aug 2023 Status changed from not yet recruiting to recruiting.
- 25 Jul 2023 New trial record